nodes	percent_of_prediction	percent_of_DWPC	metapath
Probenecid—ABCC6—Dactinomycin—testicular cancer	0.0813	0.0985	CbGbCtD
Probenecid—ABCC11—Methotrexate—testicular cancer	0.0528	0.0639	CbGbCtD
Probenecid—ABCC6—Vinblastine—testicular cancer	0.0509	0.0617	CbGbCtD
Probenecid—ABCC6—Cisplatin—testicular cancer	0.0467	0.0566	CbGbCtD
Probenecid—ABCC6—Etoposide—testicular cancer	0.0459	0.0556	CbGbCtD
Probenecid—SLCO1A2—Chlorambucil—testicular cancer	0.0446	0.054	CbGbCtD
Probenecid—ABCC5—Cisplatin—testicular cancer	0.0357	0.0432	CbGbCtD
Probenecid—ABCC6—Doxorubicin—testicular cancer	0.0313	0.0379	CbGbCtD
Probenecid—ABCC1—Dactinomycin—testicular cancer	0.024	0.0291	CbGbCtD
Probenecid—SLCO1C1—Methotrexate—testicular cancer	0.0232	0.0281	CbGbCtD
Probenecid—SLC16A1—Methotrexate—testicular cancer	0.0232	0.0281	CbGbCtD
Probenecid—SLC22A5—Dactinomycin—testicular cancer	0.0228	0.0276	CbGbCtD
Probenecid—ABCC3—Cisplatin—testicular cancer	0.0224	0.0272	CbGbCtD
Probenecid—ABCC3—Etoposide—testicular cancer	0.022	0.0267	CbGbCtD
Probenecid—SLC2A9—Facilitative Na+-independent glucose transporters—SLC2A6—testicular cancer	0.0206	0.309	CbGpPWpGaD
Probenecid—ABCC1—Epirubicin—testicular cancer	0.0174	0.021	CbGbCtD
Probenecid—ABCC3—Doxorubicin—testicular cancer	0.015	0.0182	CbGbCtD
Probenecid—ABCC1—Vinblastine—testicular cancer	0.015	0.0182	CbGbCtD
Probenecid—ABCC3—Methotrexate—testicular cancer	0.0146	0.0176	CbGbCtD
Probenecid—SLC22A2—Vinblastine—testicular cancer	0.0136	0.0165	CbGbCtD
Probenecid—ABCC1—Etoposide—testicular cancer	0.0135	0.0164	CbGbCtD
Probenecid—SLC22A2—Cisplatin—testicular cancer	0.0125	0.0151	CbGbCtD
Probenecid—SLC22A11—Methotrexate—testicular cancer	0.012	0.0145	CbGbCtD
Probenecid—ABCC2—Carboplatin—testicular cancer	0.0119	0.0145	CbGbCtD
Probenecid—SLC22A7—Methotrexate—testicular cancer	0.0114	0.0138	CbGbCtD
Probenecid—ABCC4—Methotrexate—testicular cancer	0.0111	0.0135	CbGbCtD
Probenecid—ABCC2—Vinblastine—testicular cancer	0.0111	0.0135	CbGbCtD
Probenecid—ABCC2—Cisplatin—testicular cancer	0.0102	0.0124	CbGbCtD
Probenecid—CYP2C8—Ifosfamide—testicular cancer	0.0101	0.0122	CbGbCtD
Probenecid—ABCC2—Etoposide—testicular cancer	0.01	0.0121	CbGbCtD
Probenecid—ABCC1—Doxorubicin—testicular cancer	0.00923	0.0112	CbGbCtD
Probenecid—ABCC1—Methotrexate—testicular cancer	0.00894	0.0108	CbGbCtD
Probenecid—CYP2C19—Ifosfamide—testicular cancer	0.00847	0.0103	CbGbCtD
Probenecid—SLCO1A2—Methotrexate—testicular cancer	0.00798	0.00967	CbGbCtD
Probenecid—CYP2C9—Ifosfamide—testicular cancer	0.00704	0.00853	CbGbCtD
Probenecid—SLC22A8—Methotrexate—testicular cancer	0.00695	0.00842	CbGbCtD
Probenecid—ABCC2—Doxorubicin—testicular cancer	0.00683	0.00828	CbGbCtD
Probenecid—ABCC2—Methotrexate—testicular cancer	0.00662	0.00802	CbGbCtD
Probenecid—ABCB1—Dactinomycin—testicular cancer	0.00579	0.00701	CbGbCtD
Probenecid—SLC22A6—Methotrexate—testicular cancer	0.00484	0.00587	CbGbCtD
Probenecid—CYP2C8—Etoposide—testicular cancer	0.00482	0.00585	CbGbCtD
Probenecid—ALB—Methotrexate—testicular cancer	0.00413	0.005	CbGbCtD
Probenecid—CYP3A4—Ifosfamide—testicular cancer	0.00409	0.00496	CbGbCtD
Probenecid—ABCB1—Vinblastine—testicular cancer	0.00363	0.00439	CbGbCtD
Probenecid—SLC2A9—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00361	0.0541	CbGpPWpGaD
Probenecid—CYP2C9—Cisplatin—testicular cancer	0.00342	0.00415	CbGbCtD
Probenecid—ABCC11—embryo—testicular cancer	0.0034	0.0707	CbGeAlD
Probenecid—PANX1—seminal vesicle—testicular cancer	0.00334	0.0692	CbGeAlD
Probenecid—ABCB1—Cisplatin—testicular cancer	0.00332	0.00403	CbGbCtD
Probenecid—SLC22A12—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.0033	0.0495	CbGpPWpGaD
Probenecid—ABCB1—Etoposide—testicular cancer	0.00327	0.00396	CbGbCtD
Probenecid—SLC2A9—seminal vesicle—testicular cancer	0.00302	0.0628	CbGeAlD
Probenecid—SLC16A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00294	0.0441	CbGpPWpGaD
Probenecid—Nephrotic syndrome—Chlorambucil—testicular cancer	0.0029	0.0507	CcSEcCtD
Probenecid—SLC2A9—NRF2 pathway—SLC2A6—testicular cancer	0.0026	0.039	CbGpPWpGaD
Probenecid—ABCC6—Podofilox—Etoposide—testicular cancer	0.00252	1	CbGdCrCtD
Probenecid—ABCC11—gonad—testicular cancer	0.00231	0.048	CbGeAlD
Probenecid—ABCB1—Doxorubicin—testicular cancer	0.00223	0.0027	CbGbCtD
Probenecid—CYP3A4—Vinblastine—testicular cancer	0.00217	0.00263	CbGbCtD
Probenecid—ABCB1—Methotrexate—testicular cancer	0.00216	0.00261	CbGbCtD
Probenecid—PANX1—female gonad—testicular cancer	0.00196	0.0407	CbGeAlD
Probenecid—CYP3A4—Etoposide—testicular cancer	0.00196	0.00237	CbGbCtD
Probenecid—ABCC11—female gonad—testicular cancer	0.00188	0.039	CbGeAlD
Probenecid—SLC2A9—female gonad—testicular cancer	0.00178	0.0369	CbGeAlD
Probenecid—PANX1—testis—testicular cancer	0.00174	0.0361	CbGeAlD
Probenecid—SLC10A1—seminal vesicle—testicular cancer	0.00167	0.0346	CbGeAlD
Probenecid—ABCC11—testis—testicular cancer	0.00167	0.0346	CbGeAlD
Probenecid—SLC2A9—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00164	0.0246	CbGpPWpGaD
Probenecid—SLC2A9—testis—testicular cancer	0.00158	0.0327	CbGeAlD
Probenecid—SLC22A12—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0015	0.0225	CbGpPWpGaD
Probenecid—SLC16A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00134	0.02	CbGpPWpGaD
Probenecid—CYP3A4—Doxorubicin—testicular cancer	0.00133	0.00162	CbGbCtD
Probenecid—SLC16A7—gonad—testicular cancer	0.00129	0.0268	CbGeAlD
Probenecid—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00128	0.0192	CbGpPWpGaD
Probenecid—PANX1—lymph node—testicular cancer	0.00126	0.0261	CbGeAlD
Probenecid—SLC16A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00126	0.0188	CbGpPWpGaD
Probenecid—SLC10A1—gonad—testicular cancer	0.0012	0.025	CbGeAlD
Probenecid—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00116	0.0174	CbGpPWpGaD
Probenecid—SLC2A9—lymph node—testicular cancer	0.00114	0.0237	CbGeAlD
Probenecid—Haemolytic anaemia—Chlorambucil—testicular cancer	0.00113	0.0197	CcSEcCtD
Probenecid—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00108	0.0162	CbGpPWpGaD
Probenecid—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000977	0.0146	CbGpPWpGaD
Probenecid—ABCC5—NRF2 pathway—SLC2A6—testicular cancer	0.000974	0.0146	CbGpPWpGaD
Probenecid—Aplastic anaemia—Dactinomycin—testicular cancer	0.00095	0.0166	CcSEcCtD
Probenecid—SLC16A7—testis—testicular cancer	0.000929	0.0193	CbGeAlD
Probenecid—Toxic epidermal necrolysis—Chlorambucil—testicular cancer	0.000916	0.016	CcSEcCtD
Probenecid—ABCC11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000896	0.0134	CbGpPWpGaD
Probenecid—SLCO1C1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000886	0.0133	CbGpPWpGaD
Probenecid—SLC10A1—testis—testicular cancer	0.000868	0.018	CbGeAlD
Probenecid—SLC2A9—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000833	0.0125	CbGpPWpGaD
Probenecid—Pain—Carboplatin—testicular cancer	0.000831	0.0145	CcSEcCtD
Probenecid—SLC16A1—gonad—testicular cancer	0.000821	0.017	CbGeAlD
Probenecid—SLCO1C1—testis—testicular cancer	0.000816	0.0169	CbGeAlD
Probenecid—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000815	0.0122	CbGpPWpGaD
Probenecid—Stevens-Johnson syndrome—Chlorambucil—testicular cancer	0.000777	0.0136	CcSEcCtD
Probenecid—SLC22A7—testis—testicular cancer	0.000774	0.0161	CbGeAlD
Probenecid—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.000772	0.0116	CbGpPWpGaD
Probenecid—Body temperature increased—Carboplatin—testicular cancer	0.000769	0.0134	CcSEcCtD
Probenecid—SLC22A12—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000762	0.0114	CbGpPWpGaD
Probenecid—Haemolytic anaemia—Ifosfamide—testicular cancer	0.000746	0.013	CcSEcCtD
Probenecid—ABCC1—seminal vesicle—testicular cancer	0.000738	0.0153	CbGeAlD
Probenecid—ABCC5—female gonad—testicular cancer	0.000733	0.0152	CbGeAlD
Probenecid—ABCC3—NRF2 pathway—SLC2A6—testicular cancer	0.000718	0.0108	CbGpPWpGaD
Probenecid—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00068	0.0102	CbGpPWpGaD
Probenecid—SLC16A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000679	0.0102	CbGpPWpGaD
Probenecid—ABCC6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000679	0.0102	CbGpPWpGaD
Probenecid—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.000675	0.0101	CbGpPWpGaD
Probenecid—SLC16A7—lymph node—testicular cancer	0.000674	0.014	CbGeAlD
Probenecid—SLC16A1—female gonad—testicular cancer	0.000667	0.0138	CbGeAlD
Probenecid—Erythema multiforme—Chlorambucil—testicular cancer	0.000666	0.0116	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Dactinomycin—testicular cancer	0.000661	0.0116	CcSEcCtD
Probenecid—ABCC5—testis—testicular cancer	0.00065	0.0135	CbGeAlD
Probenecid—SLC22A5—seminal vesicle—testicular cancer	0.000649	0.0135	CbGeAlD
Probenecid—Haemolytic anaemia—Cisplatin—testicular cancer	0.000643	0.0112	CcSEcCtD
Probenecid—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000633	0.00949	CbGpPWpGaD
Probenecid—Alopecia—Chlorambucil—testicular cancer	0.000622	0.0109	CcSEcCtD
Probenecid—ABCC3—female gonad—testicular cancer	0.000616	0.0128	CbGeAlD
Probenecid—Toxic epidermal necrolysis—Ifosfamide—testicular cancer	0.000606	0.0106	CcSEcCtD
Probenecid—SLC16A1—testis—testicular cancer	0.000592	0.0123	CbGeAlD
Probenecid—SLCO1C1—lymph node—testicular cancer	0.000592	0.0123	CbGeAlD
Probenecid—SLC22A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000582	0.00872	CbGpPWpGaD
Probenecid—Haematuria—Bleomycin—testicular cancer	0.000579	0.0101	CcSEcCtD
Probenecid—SLC16A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000571	0.00855	CbGpPWpGaD
Probenecid—Alopecia—Vinblastine—testicular cancer	0.00057	0.00997	CcSEcCtD
Probenecid—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.000569	0.00853	CbGpPWpGaD
Probenecid—Anaemia—Chlorambucil—testicular cancer	0.000566	0.0099	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Dactinomycin—testicular cancer	0.000561	0.00981	CcSEcCtD
Probenecid—Leukopenia—Chlorambucil—testicular cancer	0.000549	0.00959	CcSEcCtD
Probenecid—ABCC3—testis—testicular cancer	0.000546	0.0113	CbGeAlD
Probenecid—Pollakiuria—Ifosfamide—testicular cancer	0.000537	0.0094	CcSEcCtD
Probenecid—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000528	0.00791	CbGpPWpGaD
Probenecid—Anaemia—Vinblastine—testicular cancer	0.000519	0.00908	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Ifosfamide—testicular cancer	0.000514	0.00899	CcSEcCtD
Probenecid—ABCC4—female gonad—testicular cancer	0.000508	0.0105	CbGeAlD
Probenecid—Flushing—Bleomycin—testicular cancer	0.000506	0.00884	CcSEcCtD
Probenecid—Leukopenia—Vinblastine—testicular cancer	0.000503	0.00879	CcSEcCtD
Probenecid—Haematuria—Ifosfamide—testicular cancer	0.000495	0.00865	CcSEcCtD
Probenecid—SLC22A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000491	0.00736	CbGpPWpGaD
Probenecid—Alopecia—Bleomycin—testicular cancer	0.000481	0.00842	CcSEcCtD
Probenecid—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000481	0.00721	CbGpPWpGaD
Probenecid—Erythema multiforme—Dactinomycin—testicular cancer	0.00048	0.0084	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.000479	0.00837	CcSEcCtD
Probenecid—Anorexia—Chlorambucil—testicular cancer	0.000477	0.00834	CcSEcCtD
Probenecid—Flushing—Dactinomycin—testicular cancer	0.000472	0.00825	CcSEcCtD
Probenecid—ABCC5—lymph node—testicular cancer	0.000471	0.00978	CbGeAlD
Probenecid—SLCO1A2—testis—testicular cancer	0.000468	0.00972	CbGeAlD
Probenecid—ALB—testis—testicular cancer	0.000466	0.00967	CbGeAlD
Probenecid—ABCC4—testis—testicular cancer	0.000451	0.00936	CbGeAlD
Probenecid—SLCO1C1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00045	0.00675	CbGpPWpGaD
Probenecid—Alopecia—Dactinomycin—testicular cancer	0.000449	0.00785	CcSEcCtD
Probenecid—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000444	0.00665	CbGpPWpGaD
Probenecid—Erythema multiforme—Ifosfamide—testicular cancer	0.00044	0.0077	CcSEcCtD
Probenecid—Anaemia—Bleomycin—testicular cancer	0.000438	0.00767	CcSEcCtD
Probenecid—Anorexia—Vinblastine—testicular cancer	0.000437	0.00764	CcSEcCtD
Probenecid—ABCC2—testis—testicular cancer	0.000436	0.00906	CbGeAlD
Probenecid—PANX1—Innate Immune System—BCL10—testicular cancer	0.000435	0.00652	CbGpPWpGaD
Probenecid—Decreased appetite—Chlorambucil—testicular cancer	0.000435	0.0076	CcSEcCtD
Probenecid—ABCC1—female gonad—testicular cancer	0.000433	0.00899	CbGeAlD
Probenecid—Flushing—Ifosfamide—testicular cancer	0.000432	0.00756	CcSEcCtD
Probenecid—SLC16A1—lymph node—testicular cancer	0.000429	0.0089	CbGeAlD
Probenecid—Pain—Chlorambucil—testicular cancer	0.000428	0.00748	CcSEcCtD
Probenecid—Leukopenia—Bleomycin—testicular cancer	0.000425	0.00742	CcSEcCtD
Probenecid—Aplastic anaemia—Methotrexate—testicular cancer	0.000412	0.0072	CcSEcCtD
Probenecid—Alopecia—Ifosfamide—testicular cancer	0.000411	0.00719	CcSEcCtD
Probenecid—Anaemia—Dactinomycin—testicular cancer	0.000409	0.00715	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Etoposide—testicular cancer	0.000406	0.0071	CcSEcCtD
Probenecid—Decreased appetite—Vinblastine—testicular cancer	0.000398	0.00697	CcSEcCtD
Probenecid—Urticaria—Chlorambucil—testicular cancer	0.000397	0.00695	CcSEcCtD
Probenecid—Leukopenia—Dactinomycin—testicular cancer	0.000396	0.00692	CcSEcCtD
Probenecid—ABCC3—lymph node—testicular cancer	0.000396	0.00822	CbGeAlD
Probenecid—Body temperature increased—Chlorambucil—testicular cancer	0.000395	0.00691	CcSEcCtD
Probenecid—SLCO1A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000394	0.00591	CbGpPWpGaD
Probenecid—Pain—Vinblastine—testicular cancer	0.000392	0.00685	CcSEcCtD
Probenecid—Anaphylactic shock—Bleomycin—testicular cancer	0.000387	0.00677	CcSEcCtD
Probenecid—Aplastic anaemia—Epirubicin—testicular cancer	0.000385	0.00674	CcSEcCtD
Probenecid—ABCC1—testis—testicular cancer	0.000384	0.00798	CbGeAlD
Probenecid—SLC22A5—female gonad—testicular cancer	0.000381	0.00791	CbGeAlD
Probenecid—Anaemia—Ifosfamide—testicular cancer	0.000375	0.00655	CcSEcCtD
Probenecid—Flushing—Cisplatin—testicular cancer	0.000373	0.00651	CcSEcCtD
Probenecid—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00037	0.00555	CbGpPWpGaD
Probenecid—Anorexia—Bleomycin—testicular cancer	0.000369	0.00645	CcSEcCtD
Probenecid—Hypersensitivity—Chlorambucil—testicular cancer	0.000368	0.00644	CcSEcCtD
Probenecid—Leukopenia—Ifosfamide—testicular cancer	0.000363	0.00634	CcSEcCtD
Probenecid—Aplastic anaemia—Doxorubicin—testicular cancer	0.000357	0.00624	CcSEcCtD
Probenecid—Alopecia—Cisplatin—testicular cancer	0.000355	0.0062	CcSEcCtD
Probenecid—Pruritus—Chlorambucil—testicular cancer	0.000354	0.00619	CcSEcCtD
Probenecid—Erythema multiforme—Etoposide—testicular cancer	0.000348	0.00608	CcSEcCtD
Probenecid—Anorexia—Dactinomycin—testicular cancer	0.000344	0.00602	CcSEcCtD
Probenecid—Flushing—Etoposide—testicular cancer	0.000341	0.00597	CcSEcCtD
Probenecid—SLC22A5—testis—testicular cancer	0.000338	0.00702	CbGeAlD
Probenecid—Hypersensitivity—Vinblastine—testicular cancer	0.000338	0.0059	CcSEcCtD
Probenecid—ALB—lymph node—testicular cancer	0.000338	0.00701	CbGeAlD
Probenecid—Decreased appetite—Bleomycin—testicular cancer	0.000336	0.00588	CcSEcCtD
Probenecid—Pain—Bleomycin—testicular cancer	0.000331	0.00579	CcSEcCtD
Probenecid—Anaphylactic shock—Ifosfamide—testicular cancer	0.000331	0.00578	CcSEcCtD
Probenecid—CYP2C8—testis—testicular cancer	0.000327	0.00679	CbGeAlD
Probenecid—ABCC4—lymph node—testicular cancer	0.000327	0.00678	CbGeAlD
Probenecid—Alopecia—Etoposide—testicular cancer	0.000325	0.00568	CcSEcCtD
Probenecid—Anaemia—Cisplatin—testicular cancer	0.000323	0.00565	CcSEcCtD
Probenecid—ABCB1—embryo—testicular cancer	0.000321	0.00666	CbGeAlD
Probenecid—Vomiting—Chlorambucil—testicular cancer	0.000318	0.00556	CcSEcCtD
Probenecid—ABCC2—lymph node—testicular cancer	0.000316	0.00656	CbGeAlD
Probenecid—Anorexia—Ifosfamide—testicular cancer	0.000315	0.00551	CcSEcCtD
Probenecid—Decreased appetite—Dactinomycin—testicular cancer	0.000314	0.00549	CcSEcCtD
Probenecid—Leukopenia—Cisplatin—testicular cancer	0.000313	0.00547	CcSEcCtD
Probenecid—ABCC5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000312	0.00468	CbGpPWpGaD
Probenecid—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000309	0.00463	CbGpPWpGaD
Probenecid—Pain—Dactinomycin—testicular cancer	0.000309	0.0054	CcSEcCtD
Probenecid—Urticaria—Bleomycin—testicular cancer	0.000308	0.00538	CcSEcCtD
Probenecid—Body temperature increased—Bleomycin—testicular cancer	0.000306	0.00535	CcSEcCtD
Probenecid—Dizziness—Vinblastine—testicular cancer	0.000303	0.0053	CcSEcCtD
Probenecid—ABCB1—seminal vesicle—testicular cancer	0.000301	0.00625	CbGeAlD
Probenecid—Nausea—Chlorambucil—testicular cancer	0.000297	0.00519	CcSEcCtD
Probenecid—Anaemia—Etoposide—testicular cancer	0.000296	0.00517	CcSEcCtD
Probenecid—SLC22A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000296	0.00443	CbGpPWpGaD
Probenecid—Vomiting—Vinblastine—testicular cancer	0.000291	0.0051	CcSEcCtD
Probenecid—SLC16A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00029	0.00435	CbGpPWpGaD
Probenecid—SLC22A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000288	0.00431	CbGpPWpGaD
Probenecid—Decreased appetite—Ifosfamide—testicular cancer	0.000288	0.00503	CcSEcCtD
Probenecid—Headache—Vinblastine—testicular cancer	0.000287	0.00502	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000287	0.00501	CcSEcCtD
Probenecid—Leukopenia—Etoposide—testicular cancer	0.000287	0.00501	CcSEcCtD
Probenecid—Body temperature increased—Dactinomycin—testicular cancer	0.000285	0.00499	CcSEcCtD
Probenecid—Anaphylactic shock—Cisplatin—testicular cancer	0.000285	0.00499	CcSEcCtD
Probenecid—Hypersensitivity—Bleomycin—testicular cancer	0.000285	0.00499	CcSEcCtD
Probenecid—Pain—Ifosfamide—testicular cancer	0.000283	0.00495	CcSEcCtD
Probenecid—ABCC1—lymph node—testicular cancer	0.000279	0.00578	CbGeAlD
Probenecid—Pruritus—Bleomycin—testicular cancer	0.000274	0.00479	CcSEcCtD
Probenecid—Nausea—Vinblastine—testicular cancer	0.000272	0.00476	CcSEcCtD
Probenecid—Anorexia—Cisplatin—testicular cancer	0.000272	0.00475	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000268	0.00469	CcSEcCtD
Probenecid—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000268	0.00402	CbGpPWpGaD
Probenecid—Hypersensitivity—Dactinomycin—testicular cancer	0.000266	0.00465	CcSEcCtD
Probenecid—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000263	0.00394	CbGpPWpGaD
Probenecid—Urticaria—Ifosfamide—testicular cancer	0.000263	0.0046	CcSEcCtD
Probenecid—PANX1—Innate Immune System—KITLG—testicular cancer	0.000262	0.00393	CbGpPWpGaD
Probenecid—Body temperature increased—Ifosfamide—testicular cancer	0.000262	0.00457	CcSEcCtD
Probenecid—Anaphylactic shock—Etoposide—testicular cancer	0.000261	0.00457	CcSEcCtD
Probenecid—PANX1—Immune System—BCL10—testicular cancer	0.000253	0.0038	CbGpPWpGaD
Probenecid—SLC22A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000249	0.00374	CbGpPWpGaD
Probenecid—Anorexia—Etoposide—testicular cancer	0.000249	0.00435	CcSEcCtD
Probenecid—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000248	0.00434	CcSEcCtD
Probenecid—Decreased appetite—Cisplatin—testicular cancer	0.000248	0.00434	CcSEcCtD
Probenecid—Vomiting—Bleomycin—testicular cancer	0.000246	0.0043	CcSEcCtD
Probenecid—SLC22A5—lymph node—testicular cancer	0.000245	0.00509	CbGeAlD
Probenecid—Pain—Cisplatin—testicular cancer	0.000244	0.00426	CcSEcCtD
Probenecid—Dermatitis—Bleomycin—testicular cancer	0.000244	0.00426	CcSEcCtD
Probenecid—Hypersensitivity—Ifosfamide—testicular cancer	0.000244	0.00426	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000243	0.00425	CcSEcCtD
Probenecid—Pollakiuria—Epirubicin—testicular cancer	0.000238	0.00416	CcSEcCtD
Probenecid—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000235	0.00352	CbGpPWpGaD
Probenecid—Pruritus—Ifosfamide—testicular cancer	0.000234	0.00409	CcSEcCtD
Probenecid—Haematuria—Methotrexate—testicular cancer	0.000234	0.00409	CcSEcCtD
Probenecid—ABCC3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00023	0.00345	CbGpPWpGaD
Probenecid—Nausea—Bleomycin—testicular cancer	0.00023	0.00402	CcSEcCtD
Probenecid—Vomiting—Dactinomycin—testicular cancer	0.00023	0.00401	CcSEcCtD
Probenecid—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000228	0.00398	CcSEcCtD
Probenecid—Decreased appetite—Etoposide—testicular cancer	0.000227	0.00397	CcSEcCtD
Probenecid—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000226	0.00338	CbGpPWpGaD
Probenecid—Body temperature increased—Cisplatin—testicular cancer	0.000225	0.00394	CcSEcCtD
Probenecid—Pain—Etoposide—testicular cancer	0.000223	0.00391	CcSEcCtD
Probenecid—Pollakiuria—Doxorubicin—testicular cancer	0.00022	0.00385	CcSEcCtD
Probenecid—Haematuria—Epirubicin—testicular cancer	0.000219	0.00383	CcSEcCtD
Probenecid—Dizziness—Ifosfamide—testicular cancer	0.000219	0.00383	CcSEcCtD
Probenecid—ABCB1—gonad—testicular cancer	0.000218	0.00452	CbGeAlD
Probenecid—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000216	0.00324	CbGpPWpGaD
Probenecid—Nausea—Dactinomycin—testicular cancer	0.000214	0.00375	CcSEcCtD
Probenecid—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000214	0.00321	CbGpPWpGaD
Probenecid—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000211	0.00368	CcSEcCtD
Probenecid—Vomiting—Ifosfamide—testicular cancer	0.00021	0.00368	CcSEcCtD
Probenecid—Hypersensitivity—Cisplatin—testicular cancer	0.00021	0.00367	CcSEcCtD
Probenecid—Dermatitis—Ifosfamide—testicular cancer	0.000208	0.00364	CcSEcCtD
Probenecid—Erythema multiforme—Methotrexate—testicular cancer	0.000208	0.00364	CcSEcCtD
Probenecid—Urticaria—Etoposide—testicular cancer	0.000208	0.00363	CcSEcCtD
Probenecid—Body temperature increased—Etoposide—testicular cancer	0.000207	0.00361	CcSEcCtD
Probenecid—Haematuria—Doxorubicin—testicular cancer	0.000203	0.00354	CcSEcCtD
Probenecid—SLCO1A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0002	0.003	CbGpPWpGaD
Probenecid—Nausea—Ifosfamide—testicular cancer	0.000197	0.00344	CcSEcCtD
Probenecid—PANX1—Innate Immune System—FGFR3—testicular cancer	0.000195	0.00292	CbGpPWpGaD
Probenecid—Erythema multiforme—Epirubicin—testicular cancer	0.000195	0.00341	CcSEcCtD
Probenecid—Alopecia—Methotrexate—testicular cancer	0.000195	0.0034	CcSEcCtD
Probenecid—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000193	0.00289	CbGpPWpGaD
Probenecid—Hypersensitivity—Etoposide—testicular cancer	0.000193	0.00337	CcSEcCtD
Probenecid—Flushing—Epirubicin—testicular cancer	0.000191	0.00335	CcSEcCtD
Probenecid—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000188	0.00282	CbGpPWpGaD
Probenecid—Pruritus—Etoposide—testicular cancer	0.000185	0.00323	CcSEcCtD
Probenecid—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000182	0.00273	CbGpPWpGaD
Probenecid—Alopecia—Epirubicin—testicular cancer	0.000182	0.00319	CcSEcCtD
Probenecid—Vomiting—Cisplatin—testicular cancer	0.000181	0.00317	CcSEcCtD
Probenecid—Erythema multiforme—Doxorubicin—testicular cancer	0.00018	0.00315	CcSEcCtD
Probenecid—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00018	0.0027	CbGpPWpGaD
Probenecid—Dermatitis—Cisplatin—testicular cancer	0.00018	0.00314	CcSEcCtD
Probenecid—PANX1—Innate Immune System—KIT—testicular cancer	0.000179	0.00268	CbGpPWpGaD
Probenecid—Anaemia—Methotrexate—testicular cancer	0.000177	0.0031	CcSEcCtD
Probenecid—Flushing—Doxorubicin—testicular cancer	0.000177	0.0031	CcSEcCtD
Probenecid—ABCB1—female gonad—testicular cancer	0.000177	0.00367	CbGeAlD
Probenecid—Dizziness—Etoposide—testicular cancer	0.000173	0.00302	CcSEcCtD
Probenecid—Leukopenia—Methotrexate—testicular cancer	0.000172	0.003	CcSEcCtD
Probenecid—Nausea—Cisplatin—testicular cancer	0.000169	0.00296	CcSEcCtD
Probenecid—Alopecia—Doxorubicin—testicular cancer	0.000169	0.00295	CcSEcCtD
Probenecid—Vomiting—Etoposide—testicular cancer	0.000166	0.0029	CcSEcCtD
Probenecid—Anaemia—Epirubicin—testicular cancer	0.000166	0.0029	CcSEcCtD
Probenecid—Dermatitis—Etoposide—testicular cancer	0.000165	0.00288	CcSEcCtD
Probenecid—Headache—Etoposide—testicular cancer	0.000164	0.00286	CcSEcCtD
Probenecid—Leukopenia—Epirubicin—testicular cancer	0.000161	0.00281	CcSEcCtD
Probenecid—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000157	0.00235	CbGpPWpGaD
Probenecid—ABCB1—testis—testicular cancer	0.000157	0.00326	CbGeAlD
Probenecid—Anaphylactic shock—Methotrexate—testicular cancer	0.000157	0.00274	CcSEcCtD
Probenecid—SLC10A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000155	0.00233	CbGpPWpGaD
Probenecid—Nausea—Etoposide—testicular cancer	0.000155	0.00271	CcSEcCtD
Probenecid—Anaemia—Doxorubicin—testicular cancer	0.000153	0.00268	CcSEcCtD
Probenecid—PANX1—Immune System—KITLG—testicular cancer	0.000153	0.00229	CbGpPWpGaD
Probenecid—Anorexia—Methotrexate—testicular cancer	0.000149	0.00261	CcSEcCtD
Probenecid—Leukopenia—Doxorubicin—testicular cancer	0.000149	0.0026	CcSEcCtD
Probenecid—Anaphylactic shock—Epirubicin—testicular cancer	0.000146	0.00256	CcSEcCtD
Probenecid—SLC22A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000146	0.00219	CbGpPWpGaD
Probenecid—Anorexia—Epirubicin—testicular cancer	0.00014	0.00244	CcSEcCtD
Probenecid—Decreased appetite—Methotrexate—testicular cancer	0.000136	0.00238	CcSEcCtD
Probenecid—Anaphylactic shock—Doxorubicin—testicular cancer	0.000136	0.00237	CcSEcCtD
Probenecid—Pain—Methotrexate—testicular cancer	0.000134	0.00234	CcSEcCtD
Probenecid—Anorexia—Doxorubicin—testicular cancer	0.000129	0.00226	CcSEcCtD
Probenecid—Decreased appetite—Epirubicin—testicular cancer	0.000127	0.00223	CcSEcCtD
Probenecid—Pain—Epirubicin—testicular cancer	0.000125	0.00219	CcSEcCtD
Probenecid—Urticaria—Methotrexate—testicular cancer	0.000124	0.00217	CcSEcCtD
Probenecid—Body temperature increased—Methotrexate—testicular cancer	0.000124	0.00216	CcSEcCtD
Probenecid—Decreased appetite—Doxorubicin—testicular cancer	0.000118	0.00206	CcSEcCtD
Probenecid—Urticaria—Epirubicin—testicular cancer	0.000116	0.00203	CcSEcCtD
Probenecid—Pain—Doxorubicin—testicular cancer	0.000116	0.00203	CcSEcCtD
Probenecid—Body temperature increased—Epirubicin—testicular cancer	0.000116	0.00202	CcSEcCtD
Probenecid—Hypersensitivity—Methotrexate—testicular cancer	0.000115	0.00202	CcSEcCtD
Probenecid—ABCB1—lymph node—testicular cancer	0.000114	0.00236	CbGeAlD
Probenecid—PANX1—Immune System—FGFR3—testicular cancer	0.000114	0.0017	CbGpPWpGaD
Probenecid—Pruritus—Methotrexate—testicular cancer	0.000111	0.00194	CcSEcCtD
Probenecid—Hypersensitivity—Epirubicin—testicular cancer	0.000108	0.00189	CcSEcCtD
Probenecid—Urticaria—Doxorubicin—testicular cancer	0.000108	0.00188	CcSEcCtD
Probenecid—Body temperature increased—Doxorubicin—testicular cancer	0.000107	0.00187	CcSEcCtD
Probenecid—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000107	0.0016	CbGpPWpGaD
Probenecid—PANX1—Immune System—KIT—testicular cancer	0.000104	0.00156	CbGpPWpGaD
Probenecid—Pruritus—Epirubicin—testicular cancer	0.000104	0.00181	CcSEcCtD
Probenecid—Dizziness—Methotrexate—testicular cancer	0.000103	0.00181	CcSEcCtD
Probenecid—Hypersensitivity—Doxorubicin—testicular cancer	9.98e-05	0.00175	CcSEcCtD
Probenecid—Vomiting—Methotrexate—testicular cancer	9.95e-05	0.00174	CcSEcCtD
Probenecid—Dermatitis—Methotrexate—testicular cancer	9.86e-05	0.00172	CcSEcCtD
Probenecid—Headache—Methotrexate—testicular cancer	9.8e-05	0.00171	CcSEcCtD
Probenecid—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.78e-05	0.00147	CbGpPWpGaD
Probenecid—CYP2C8—Biological oxidations—HPGDS—testicular cancer	9.78e-05	0.00147	CbGpPWpGaD
Probenecid—Dizziness—Epirubicin—testicular cancer	9.69e-05	0.00169	CcSEcCtD
Probenecid—Pruritus—Doxorubicin—testicular cancer	9.59e-05	0.00168	CcSEcCtD
Probenecid—Vomiting—Epirubicin—testicular cancer	9.31e-05	0.00163	CcSEcCtD
Probenecid—Nausea—Methotrexate—testicular cancer	9.3e-05	0.00163	CcSEcCtD
Probenecid—Dermatitis—Epirubicin—testicular cancer	9.23e-05	0.00161	CcSEcCtD
Probenecid—Headache—Epirubicin—testicular cancer	9.18e-05	0.0016	CcSEcCtD
Probenecid—Dizziness—Doxorubicin—testicular cancer	8.96e-05	0.00157	CcSEcCtD
Probenecid—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.78e-05	0.00132	CbGpPWpGaD
Probenecid—CYP2C19—Biological oxidations—HPGDS—testicular cancer	8.73e-05	0.00131	CbGpPWpGaD
Probenecid—Nausea—Epirubicin—testicular cancer	8.7e-05	0.00152	CcSEcCtD
Probenecid—Vomiting—Doxorubicin—testicular cancer	8.62e-05	0.00151	CcSEcCtD
Probenecid—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.57e-05	0.00128	CbGpPWpGaD
Probenecid—Dermatitis—Doxorubicin—testicular cancer	8.54e-05	0.00149	CcSEcCtD
Probenecid—Headache—Doxorubicin—testicular cancer	8.49e-05	0.00148	CcSEcCtD
Probenecid—Nausea—Doxorubicin—testicular cancer	8.05e-05	0.00141	CcSEcCtD
Probenecid—CYP2C9—Biological oxidations—HPGDS—testicular cancer	7.96e-05	0.00119	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	7.84e-05	0.00117	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.64e-05	0.00115	CbGpPWpGaD
Probenecid—SLC10A1—Metabolism—HPGDS—testicular cancer	6.92e-05	0.00104	CbGpPWpGaD
Probenecid—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.88e-05	0.00103	CbGpPWpGaD
Probenecid—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	5.69e-05	0.000853	CbGpPWpGaD
Probenecid—ABCC5—Metabolism—HPGDS—testicular cancer	5.3e-05	0.000795	CbGpPWpGaD
Probenecid—CYP3A4—Biological oxidations—HPGDS—testicular cancer	5.25e-05	0.000787	CbGpPWpGaD
Probenecid—SLC10A1—Metabolism—STK11—testicular cancer	5.03e-05	0.000753	CbGpPWpGaD
Probenecid—SLC16A1—Metabolism—HPGDS—testicular cancer	4.93e-05	0.000739	CbGpPWpGaD
Probenecid—ABCC5—Disease—H2AFZ—testicular cancer	4.63e-05	0.000694	CbGpPWpGaD
Probenecid—ABCC5—Disease—KITLG—testicular cancer	4.26e-05	0.000638	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—HPGDS—testicular cancer	3.91e-05	0.000586	CbGpPWpGaD
Probenecid—ABCC5—Metabolism—STK11—testicular cancer	3.85e-05	0.000577	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.76e-05	0.000563	CbGpPWpGaD
Probenecid—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.73e-05	0.00056	CbGpPWpGaD
Probenecid—SLC16A1—Metabolism—STK11—testicular cancer	3.58e-05	0.000537	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—HPGDS—testicular cancer	3.4e-05	0.00051	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.35e-05	0.000503	CbGpPWpGaD
Probenecid—ABCC5—Disease—FGFR3—testicular cancer	3.16e-05	0.000474	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—HPGDS—testicular cancer	3.06e-05	0.000459	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.06e-05	0.000458	CbGpPWpGaD
Probenecid—ABCC5—Disease—KIT—testicular cancer	2.9e-05	0.000435	CbGpPWpGaD
Probenecid—ABCC3—Metabolism—STK11—testicular cancer	2.84e-05	0.000426	CbGpPWpGaD
Probenecid—ABCC1—Disease—H2AFZ—testicular cancer	2.67e-05	0.000401	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—HPGDS—testicular cancer	2.67e-05	0.0004	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—HPGDS—testicular cancer	2.49e-05	0.000373	CbGpPWpGaD
Probenecid—SLCO1A2—Metabolism—STK11—testicular cancer	2.47e-05	0.000371	CbGpPWpGaD
Probenecid—ABCC1—Disease—KITLG—testicular cancer	2.46e-05	0.000369	CbGpPWpGaD
Probenecid—ABCC1—Metabolism—STK11—testicular cancer	2.23e-05	0.000334	CbGpPWpGaD
Probenecid—SLC22A2—Metabolism—STK11—testicular cancer	1.94e-05	0.000291	CbGpPWpGaD
Probenecid—ABCC1—Disease—FGFR3—testicular cancer	1.83e-05	0.000274	CbGpPWpGaD
Probenecid—SLC22A1—Metabolism—STK11—testicular cancer	1.81e-05	0.000271	CbGpPWpGaD
Probenecid—ABCC1—Disease—KIT—testicular cancer	1.68e-05	0.000251	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—HPGDS—testicular cancer	1.67e-05	0.000251	CbGpPWpGaD
Probenecid—ALB—Metabolism—HPGDS—testicular cancer	1.66e-05	0.000249	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—HPGDS—testicular cancer	1.49e-05	0.000224	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—HPGDS—testicular cancer	1.46e-05	0.000218	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—HPGDS—testicular cancer	1.36e-05	0.000204	CbGpPWpGaD
Probenecid—CYP2C8—Metabolism—STK11—testicular cancer	1.22e-05	0.000182	CbGpPWpGaD
Probenecid—ALB—Metabolism—STK11—testicular cancer	1.21e-05	0.000181	CbGpPWpGaD
Probenecid—CYP2C19—Metabolism—STK11—testicular cancer	1.08e-05	0.000163	CbGpPWpGaD
Probenecid—ABCB1—Metabolism—STK11—testicular cancer	1.06e-05	0.000159	CbGpPWpGaD
Probenecid—CYP2C9—Metabolism—STK11—testicular cancer	9.89e-06	0.000148	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—HPGDS—testicular cancer	8.98e-06	0.000135	CbGpPWpGaD
Probenecid—CYP3A4—Metabolism—STK11—testicular cancer	6.52e-06	9.78e-05	CbGpPWpGaD
